Hematology/Oncology

Top Story

FDA grants priority review to belantamab mafodotin for relapsed, refractory multiple myeloma

January 21, 2020

The FDA granted priority review to belantamab mafodotin for the treatment of patients with relapsed or refractory multiple myeloma who previously received an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, according to a press release from the drug’s manufacturer.

Belantamab mafodotin (GSK2857916, GlaxoSmithKline) is an investigational anti-B-cell maturation antigen (BCMA) monoclonal antibody-drug conjugate.

Guidelines

ASTRO issues guidelines on radiation therapy for basal, cutaneous squamous cell carcinoma

January 21, 2020

American Society for Radiation Oncology has issued guidelines on the use of radiation therapy in the management of basal and cutaneous squamous cell carcinomas. …

FDA News

FDA grants orphan drug designation to durvalumab-tremelimumab combination for liver cancer

January 21, 2020

The FDA granted orphan drug designation to the combination of durvalumab plus tremelimumab for treatment of patients with advanced hepatocellular carcinoma. Durvalumab…

FDA News

FDA grants priority review to Lynparza for prostate cancer subtype

January 21, 2020

The FDA granted priority review to olaparib for the treatment of men with metastatic castration-resistant prostate cancer and homologous recombination repair gene…

In the JournalsPerspective

FDA: Some sunscreen ingredients exceed safety threshold, but still OK to use

January 21, 2020

Six active ingredients in four different commercially-available sunscreen formulations applied by healthy study participants were systemically absorbed through the skin…

More Headlines »

CME